Jennifer Gurley
University of Arkansas for Medical Sciences
5 Papers
16 Citations
Jennifer Gurley is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Survival rate & Multiple myeloma. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie,Elias Anaissie,Frits van Rhee,Jeffrey Haessler,Klaus Hollmig,Mauricio Pineda-Roman,Michele Cottler-Fox,Abid Mohiuddin,Yazan Alsayed,Guido Tricot,Vanessa Bolejack,Maurizio Zangari,Joshua Epstein,Nathan Petty,Douglas Steward,Bonnie Jenkins,Jennifer Gurley,Ellen Sullivan,John Crowley,John D. Shaughnessy +19 more
TL;DR: Results of this phase‐2 study demonstrated that bortezomib could be safely combined with multi‐agent chemotherapy, effecting near‐complete remission status and 2‐year survival rates in more than 80% of patients.
345
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Bart Barlogie,Guido Tricot,Frits van Rhee,Edguardo Angtuaco,Ronald C. Walker,Joshua Epstein,John D. Shaughnessy,Sundar Jagannath,Vanessa Bolejack,Jennifer Gurley,Antje Hoering,David H. Vesole,Raman Desikan,David S. Siegel,Jayesh Mehta,Seema Singhal,Nikhil C. Munshi,Madhav V. Dhodapkar,Bonnie Jenkins,Michel Attal,Jean Luc Harousseau,John Crowley +21 more
TL;DR: Postenrolment overall survival (OS) and event‐free survival (EFS) were superior in the absence of CA of the hypodiploidy or deletion 13 variety and in the presence of low CRP at baseline (P = 0·001 and 0·017 respectively).
176
Suppression of abnormal karyotype predicts superior survival in multiple myeloma
Varant Arzoumanian,Antje Hoering,Jeffery R. Sawyer,F. van Rhee,Clyde Bailey,Jennifer Gurley,John D. Shaughnessy,Elias Anaissie,John Crowley,Bart Barlogie +9 more
TL;DR: The results underscore the importance of monitoring for CA and attest to the favorable prognostic consequences of CA suppression with effective therapy.
16
ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma
Varant Arzoumanian,Antje Hoering,J. Sawyer,F. van Rhee,Clyde Bailey,Jennifer Gurley,JD Shaughnessy,E Anaissie,John Crowley,B. Barlogie +9 more
- 01 Jan 2008
TL;DR: The results underscore the importance of monitoring for CA and attest to the favorable prognostic consequences of CA suppression with effective therapy.
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Bart Barlogie,Jeff Haessler,Mauricio Pineda-Roman,Elias Anaissie,Frits van Rhee,Elias Kiwan,Douglas Steward,Jennifer Gurley,Bonnie Jenkins,John Crowley +9 more
TL;DR: Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance.